13F filing recap · Q2 2013

What did ArrowMark Partners buy in Q2 2013?

Reported stock-position changes between this filing and the previous one. US-listed stocks across every ArrowMark account, including accounts that belong to no fund below.

Stock value

$339.92M

Positions

Estimated turnover

22.1%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

CITCit Group Inc$1.86Mreported value+40.0K shares PBYIPuma Biotechnology, Inc.$565.0Kreported value+12.7K shares ACADAcadia Pharmaceuticals Inc$430.0Kreported value+23.7K shares BIIBBiogen Inc.$312.0Kreported value+1.4K shares AEGRAegerion Pharmaceuticals Inc$244.0Kreported value+3.9K shares HLHecla Mining Company$69.0Kreported value+23.2K shares

Increased positions

CLVSEURClovis Oncology Inc$7.40Mreported value+99.0K shares+863.9%DRCDresser-Rand Group Inc.$5.38Mreported value+31.1K shares+53.1%MROMarathon Oil Corp$4.14Mreported value+21.7K shares+22.2%CPSSConsumer Portfolio Services, Inc.$3.61Mreported value+255.1K shares

Reduced positions

CCitigroup Inc$37.68Mreported value-267.6K shares-25.4%JPMJPMorgan Chase & Co$21.19Mreported value-398.9K shares-49.8%METMetlife, Inc.$18.54Mreported value-107.5K shares-21.0%LNGCheniere Energy, Inc.$11.19Mreported value-1.0K shares

Exited positions

IPIIntrepid Potash, Inc.$1.70Mprior reported value-90.6K shares-100.0%STRZAStarz Entertainment Corp (liberty Capital)$1.24Mprior reported value-56.1K shares-100.0%ARIAAriad Pharmaceuticals Inc$1.08Mprior reported value-59.6K shares-100.0%ARCOArcos Dorados Holdings Inc.$606.0Kprior reported value